

# Tatyana Dronova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8621669/publications.pdf>

Version: 2024-02-01

11  
papers

57  
citations

1683354

5  
h-index

1588620

8  
g-index

11  
all docs

11  
docs citations

11  
times ranked

67  
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN. , 2021, 20, 16-23.	0.3	2
2	Role of TGF- $\beta$ 2 signaling in the mechanisms of tamoxifen resistance. Cytokine and Growth Factor Reviews, 2021, 62, 62-69.	3.2	8
3	Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients. Molecular Biology, 2021, 55, 102-108.	0.4	3
4	The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Bulletin of Siberian Medicine, 2020, 19, 13-20.	0.1	2
5	ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE. Siberian Journal of Oncology, 2020, 19, 138-145.	0.1	0
6	Impact of estrogen receptor $\beta$ on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clinical and Experimental Medicine, 2019, 19, 547-556.	1.9	10
7	Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Molecular and Cellular Biochemistry, 2018, 444, 197-206.	1.4	16
8	Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. Uspehi Molekularnoj Onkologii, 2018, 5, 40-50.	0.1	6
9	The distribution pattern of ER $\beta$ expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clinical and Experimental Medicine, 2017, 17, 383-393.	1.9	10
10	Non-Smad TGF- $\beta$ 2 signaling components are possible biomarkers of tamoxifen resistance. AIP Conference Proceedings, 2017, , .	0.3	0
11	Abstract 562: Impact of ER $\beta$ expression status and ESR1 genetic variation on progression in tamoxifen-treated breast cancer patients. , 2014, , .		0